In a woman who is 38 weeks pregnant and stable on lithium, should the medication be switched to valproate for lactation?

No – Do Not Switch to Valproate for Lactation

Valproate is absolutely contraindicated in women of childbearing potential, including during lactation, due to severe teratogenic risks and neurodevelopmental harm to offspring. The patient should continue lithium with appropriate monitoring during breastfeeding, as lithium is compatible with lactation when managed properly.

Why Valproate Must Be Avoided

The FDA drug label explicitly states that valproate causes serious birth defects (spina bifida, neural tube defects in 1-2% of exposed pregnancies), cardiac malformations, and neurodevelopmental disorders including lower IQ and autism spectrum disorder 1. Valproate is contraindicated in all women of childbearing potential unless no alternatives exist and strict contraception is used 2, 1. Even for migraine prevention during lactation, guidelines explicitly list valproate as contraindicated 2.

Recent evidence suggests potential neurodevelopmental risks even from paternal valproate exposure, further emphasizing the severity of this medication's reproductive toxicity 3, 4.

Lithium During Lactation: The Preferred Approach

Lithium can be safely continued during breastfeeding with appropriate monitoring 5, 6. While lithium does transfer into breast milk, infant serum levels typically reach only 10-17% of maternal levels 6. The key is individualized management:

• Continue lithium at the lowest effective dose that maintains maternal stability
• Monitor infant lithium levels at 1 month postpartum and periodically thereafter
• Watch for infant signs: dehydration, lethargy, poor feeding, or changes in tone
• Ensure adequate hydration in both mother and infant
• Monitor maternal lithium levels more frequently postpartum as renal clearance normalizes after pregnancy 5

Three documented cases showed successful exclusive breastfeeding on lithium, with early feeding problems resolved through lactation support 6. The risk of untreated bipolar disorder relapse (up to 2/3 of women experience postpartum episodes when untreated) far outweighs the manageable risks of lithium exposure through breast milk 7.

Clinical Algorithm for This Patient

At 38 weeks pregnant, stable on lithium:

1. Continue lithium through delivery – stopping risks severe postpartum relapse
2. Adjust lithium dose immediately postpartum – expect 30-50% decrease in dose requirement as pregnancy-related increased renal clearance reverses 5
3. Check maternal lithium level 24-48 hours postpartum, then weekly for 4 weeks
4. Support breastfeeding with close monitoring:
   • Infant lithium level at 1 month
   • Weekly infant weight checks initially
   • Assess for lethargy, poor feeding, hypotonia
5. Never consider valproate as an alternative

Common Pitfalls to Avoid

• Do not discontinue lithium peripartum – the postpartum period carries the highest relapse risk in bipolar disorder 7, 8
• Do not assume lithium is incompatible with breastfeeding – this outdated belief leads to unnecessary medication switches and maternal destabilization 5, 6
• Do not switch to valproate based on lactation concerns – valproate's risks are far more severe than lithium's manageable lactation considerations 1, 7
• Do not forget to reduce lithium dose postpartum – maintaining pregnancy doses postpartum can cause toxicity as renal function normalizes 5

Alternative Considerations (If Lithium Were Truly Contraindicated)

If lithium were genuinely unsuitable, appropriate alternatives during lactation include:

• Lamotrigine – minimal breast milk transfer, safe during lactation 9, 4
• Quetiapine – first-line second-generation antipsychotic alternative 4
• Olanzapine or aripiprazole – reasonable options with monitoring 7, 8

But valproate is never an acceptable option in this population 2, 1, 7, 3, 4.